High Free Cash Flow Stocks
DCTH is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
DELCATH SYSTEMS INC (DCTH) Stock Price & Overview
NASDAQ:DCTH • US24661P8077
Current stock price
10.78 USD
+0.33 (+3.16%)
Last:
The current stock price of DCTH is 10.78 USD. Today DCTH is up by 3.16%. In the past month the price increased by 10.58%. In the past year, price decreased by -10.15%.
DCTH Key Statistics
52-Week Range8.12 - 18.23
Current DCTH stock price positioned within its 52-week range.
1-Month Range8.78 - 10.47
Current DCTH stock price positioned within its 1-month range.
- Market Cap
- 371.371M
- P/E
- 154.00
- Fwd P/E
- N/A
- EPS (TTM)
- 0.07
- Dividend Yield
- N/A
DCTH Stock Performance
Today
+3.16%
1 Week
+7.73%
1 Month
+10.58%
3 Months
+0.77%
Longer-term
6 Months -12.70%
1 Year -10.15%
2 Years +100.96%
3 Years +82.37%
5 Years -5.94%
10 Years N/A
DCTH Stock Chart
DCTH Stock Screens
DCTH currently appears in the following ChartMill screener lists.
Fastest Growing Stocks
DCTH is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
Revenue Growth Leaders
DCTH is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
Small Cap Growth Stocks
DCTH is part of our Small Cap Growth Stocks list, indicating it is a fast growing small cap stock.
DCTH Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to DCTH. When comparing the yearly performance of all stocks, DCTH is a bad performer in the overall market: 75.77% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
DCTH Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DCTH. While DCTH has a great health rating, its profitability is only average at the moment.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DCTH Earnings
On February 26, 2026 DCTH reported an EPS of -0.05 and a revenue of 20.73M. The company beat EPS expectations (20.51% surprise) and missed revenue expectations (-0.02% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.05
Revenue Reported20.728M
EPS Surprise 20.51%
Revenue Surprise -0.02%
DCTH Forecast & Estimates
13 analysts have analysed DCTH and the average price target is 22.59 USD. This implies a price increase of 109.52% is expected in the next year compared to the current price of 10.78.
For the next year, analysts expect an EPS growth of -1035% and a revenue growth 22.68% for DCTH
Analysts
Analysts84.62
Price Target22.59 (109.55%)
EPS Next Y-1035%
Revenue Next Year22.68%
DCTH Groups
Sector & Classification
DCTH Financial Highlights
Over the last trailing twelve months DCTH reported a non-GAAP Earnings per Share(EPS) of 0.07. The EPS increased by 107.14% compared to the year before.
Income Statements
Revenue(TTM)85.23M
Net Income(TTM)2.70M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.17% | ||
| ROA | 2.18% | ||
| ROE | 2.43% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%54.55%
Sales Q2Q%37.27%
EPS 1Y (TTM)107.14%
Revenue 1Y (TTM)129.08%
DCTH Ownership
Ownership
Inst Owners50.27%
Shares34.45M
Float31.61M
Ins Owners8.07%
Short Float %12.55%
Short Ratio9.07
DCTH Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 17.69 | 174.966B | ||
| ISRG | INTUITIVE SURGICAL INC | 45.86 | 163.009B | ||
| SYK | STRYKER CORP | 22.96 | 132.986B | ||
| BSX | BOSTON SCIENTIFIC CORP | 18.38 | 93.897B | ||
| IDXX | IDEXX LABORATORIES INC | 39.46 | 45.587B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.8 | 45.039B | ||
| BDX | BECTON DICKINSON AND CO | 11.38 | 44.257B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.46 | 33.688B | ||
| RMD | RESMED INC | 18.74 | 33.544B | ||
| DXCM | DEXCOM INC | 24.66 | 24.292B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.37 | 18.455B | ||
| HOLX | HOLOGIC INC | 15.48 | 16.969B | ||
| PODD | INSULET CORP | 30.97 | 13.926B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DCTH
Company Profile
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in Queensbury, New York and currently employs 156 full-time employees. The company went IPO on 2000-10-19. The firm's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Company Info
IPO: 2000-10-19
DELCATH SYSTEMS INC
566 Queensbury Avenue
Queensbury NEW YORK 10019 US
CEO: Gerard Michel
Employees: 156
Phone: 15187438892
DELCATH SYSTEMS INC / DCTH FAQ
What does DELCATH SYSTEMS INC do?
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in Queensbury, New York and currently employs 156 full-time employees. The company went IPO on 2000-10-19. The firm's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
What is the stock price of DELCATH SYSTEMS INC today?
The current stock price of DCTH is 10.78 USD. The price increased by 3.16% in the last trading session.
Does DELCATH SYSTEMS INC pay dividends?
DCTH does not pay a dividend.
How is the ChartMill rating for DELCATH SYSTEMS INC?
DCTH has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is DCTH stock listed?
DCTH stock is listed on the Nasdaq exchange.
What do analysts say about DELCATH SYSTEMS INC (DCTH) stock?
13 analysts have analysed DCTH and the average price target is 22.59 USD. This implies a price increase of 109.52% is expected in the next year compared to the current price of 10.78.
What is the employee count for DCTH stock?
DELCATH SYSTEMS INC (DCTH) currently has 156 employees.